Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Staff editor

06.05.2021

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963

This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.

Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Latest related content

Microbiome milestone: MaaT Pharma and Clinigen team up to deliver innovative oncology therapy

Sacco System: advancing probiotic science from ingredients to innovation

A gut fungus may help protect against advanced liver disease

Study reveals how skin bacteria establish and persist over time

World Microbiome Day: celebrating the invisible allies transforming health, business, and the planet

Danone Boosts Gut Health Innovation with Akkermansia Acquisition

Latest News